长、短效重组人粒细胞刺激因子治疗化疗后Ⅲ°、Ⅳ°骨髓抑制的成本-效果比较  

Cost-effectiveness analysis of long-acting versus short-acting recombinant human granulocyte stimulating factor in the treatment of III°and IV°bone marrow suppression after chemotherapy

作　　者：张夏兰 吴斌[1] 袁静 缪洁 Zhang Xialan;Wu Bin;Yuan Jing;Miao Jie(Department of Pharmacy,Suzhou Hospital of Traditional Chinese Medicine,Nanjing University of Chinese Medicine,Suzhou 215009,Jiangsu Province,China)

机构地区：[1]南京中医药大学附属苏州市中医医院药学部,苏州215009

出　　处：《中国基层医药》2023年第4期528-533,共6页Chinese Journal of Primary Medicine and Pharmacy

基　　金：江苏省药学会-奥赛康医院药学基金项目(A2019016)。

摘　　要：目的比较长效、短效重组人粒细胞刺激因子治疗化疗引起的Ⅲ°、Ⅳ°骨髓抑制成本-效果。方法收集2018年1月至2019年12月在南京中医药大学附属苏州市中医医院接受化疗后出现Ⅲ°、Ⅳ°骨髓抑制并使用重组人粒细胞刺激因子升白治疗的患者信息,分为短效重组人粒细胞刺激因子(rhG-CSF)组和长效重组人粒细胞刺激因子(PEG-rhG-CSF)组,比较两组的临床疗效、不良反应发生率和成本-效果。结果rhG-CSF组88例,年龄(63.97±11.64)岁;PEG-rhG-CSF组80例,年龄(63.26±9.09)岁,两组的基线资料差异无统计学意义(P>0.05)。rhG-CSF组总有效率为72.72%(64/88),PEG-rhG-CSF组总有效率为78.75%(63/80)(χ^(2)=0.82,P=0.360);两组相关的不良反应发生率分别为7.95%(7/88)和7.5%(6/80)(χ^(2)=0.01,P=0.910);两组平均成本分别为(124.88±113.07)元和(3159.04±505.05)元(t=51.68,P<0.01),成本-效果比分别为1.55和40.11,以rhG-CSF组为参照的PEG-rhG-CSF组增量成本效果比为505.13。结论长、短效重组人粒细胞刺激因子治疗化疗后Ⅲ、Ⅳ°骨髓抑制的疗效和相关的不良反应发生率相似,rhG-CSF组的成本-效果分析低于PEG-rhG-CSF组,应根据患者的个体情况选择合适的升白治疗方案。Objective To investigate the cost-effectiveness of long-acting versus short-acting recombinant human granulocyte stimulating factor in the treatment of III°and IV°bone marrow suppression after chemotherapy.Methods The data of patients who presented with III and IV°bone marrow suppression after chemotherapy and received treatment with recombinant human granulocyte stimulating factor from January 2018 to December 2019 were collected.These patients were divided into the short-acting recombinant human granulocyte stimulating factor group(rhG-CSF group)and the long-acting recombinant human granulocyte stimulating factor group(PEG-rhG-CSF group)group.Clinical efficacy,the incidence of adverse reactions,and cost-effectiveness were compared between the two groups.Results There were 88 patients,aged(63.97±11.64)years,in the rhG-CSF group.There were 80 patients,aged(63.26±9.09)years in the PEG-rhG-CSF group.There was no significant difference in baseline data between the two groups(P>0.05).Total response rate was 72.72%(64/88)in the rhG-CSF group and 78.75%(63/80)in the PEG-rhG-CSF group(χ^(2)=0.82,P=0.360).The incidence of related adverse reactions was 7.95%(7/88)and 7.5%(6/80)in the rhG-CSF and PEG-rhG-CSF groups respectively(χ^(2)=0.01,P=0.910).The average cost was(124.88±113.07)yuan and(3159.04±505.05)yuan in the rhG-CSF and PEG-rhG-CSF groups respectively(t=51.68,P<0.01).The cost-effectiveness ratio was 1.55 and 40.11 in the rhG-CSF and PEG-rhG-CSF groups respectively.Taking the rhG-CSF group as a reference,the incremental cost-effectiveness ratio in the PEG-rhG-CSF group was 505.13.Conclusion Long-acting and short-acting recombinant human granulocyte stimulating factors have similar curative effects and related adverse reactions in the treatment of III°and IV°bone marrow suppression after chemotherapy.The cost-effectiveness ratio of the rhG-CSF group is lower than that of the PEG-rhG-CSF group.Appropriate treatment schemes for increasing white blood cell levels should be selected based on the individual si

关 键 词：抗肿瘤联合化疗方案 骨髓抑制 重组人粒细胞刺激因子 长效重组人粒细胞刺激因子 成本-效果分析 有效性 药物经济学评价 药品不良反应 

分 类 号：R730.53[医药卫生—肿瘤]